MYRIAD GENETICS, INC.

MYGN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $326.5M
Cost of Revenue $43.3M
Gross Profit $283.3M
Gross Margin 86.7%
Operating Expenses
Research & Development $17.9M
SG&A Expense $138.9M
Operating Income $126.5M
Operating Margin 38.7%
Interest Expense
Pretax Income $136.4M
Income Tax Expense $193.0K
Net Income $84.6M
Net Margin 25.9%
EPS (Basic) $0.91
EPS (Diluted) $0.86
Shares Outstanding (Basic) 93.5M
Shares Outstanding (Diluted) 98.6M
Dividends Per Share
← Newer Page 3 of 3 Older →